Literature DB >> 365086

Interaction of chemotherapy and immune defenses in experimental murine cryptococcosis.

J R Graybill, P C Craven, L F Mitchell, D J Drutz.   

Abstract

Congenitally athymic nude (nu/nu) and thymus-containing heterozygous (nu/X) mice were infected intraperitoneally with Cryptococcus neoformans over a wide range of challenge doses. Cryptococcal disease progressed more rapidly in nude mice than in their nu/X littermates. When nu/X mice were treated with amphotericin B, all survived an otherwise lethal dose of C. neoformans. At larger challenge doses, survival was prolonged in nu/nu mice treated with amphotericin B, but they later succumbed to cryptococcosis. At lower challenge doses, amphotericin B was curative in some nude mice. Therapy of nude mice with both amphotericin B and flucytosine further prolonged survival at high-dose challenge and increased the number of cures at low-dose challenge. These studies support an interaction of antifungal chemotherapy with thymus-dependent immune defense mechanisms. This interaction is most evident at high challenge doses, where antifungal chemotherapy cures nu/X mice but only modestly prolongs survival in nude mice.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 365086      PMCID: PMC352531          DOI: 10.1128/AAC.14.5.659

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

1.  Therapy of cryptococcosis with a combination of flucytosine and amphotericin B.

Authors:  J P Utz; I L Garriques; M A Sande; J F Warner; G L Mandell; R F McGehee; R J Duma; S Shadomy
Journal:  J Infect Dis       Date:  1975-10       Impact factor: 5.226

2.  Experimental mycobacterial infection in congenitally athymic "nude" mice.

Authors:  K Ueda; S Yamazaki; S Someya
Journal:  J Reticuloendothel Soc       Date:  1976-02

3.  Tumoricidal responses in vitro of peritoneal macrophages from conventionally housed and germ-free nude mice.

Authors:  M S Meltzer
Journal:  Cell Immunol       Date:  1976-03-01       Impact factor: 4.868

4.  Enhanced primary resistance to Listeria monocytogenes in T cell-deprived mice.

Authors:  C Chan; P A Kongshavn; E Skamene
Journal:  Immunology       Date:  1977-04       Impact factor: 7.397

5.  Rapid, simple bioassay for 5-fluorocytosine in the presence of amphotericin B.

Authors:  R L Kaspar; D J Drutz
Journal:  Antimicrob Agents Chemother       Date:  1975-04       Impact factor: 5.191

6.  Abnormalities in cell-mediated immunity in patients with Cryptococcus neoformans infection.

Authors:  S C Schimpff; J E Bennett
Journal:  J Allergy Clin Immunol       Date:  1975-06       Impact factor: 10.793

7.  Host defense in cryptococcosis. I. An in vivo model for evaluating immune response.

Authors:  J R Graybill; R L Taylor
Journal:  Int Arch Allergy Appl Immunol       Date:  1978

8.  Treatment of experimental murine cryptococcosis: a comparison of miconazole and amphotericin B.

Authors:  J R Graybill; L Mitchell; H B Levine
Journal:  Antimicrob Agents Chemother       Date:  1978-02       Impact factor: 5.191

9.  Nocardia infections in congenitally athymic (nude) mice and in other inbred mouse strains.

Authors:  P I Folb; A Timme; A Horowitz
Journal:  Infect Immun       Date:  1977-11       Impact factor: 3.441

10.  Anomalous high native resistance to athymic mice to bacterial pathogens.

Authors:  A D Nickol; P F Bonventre
Journal:  Infect Immun       Date:  1977-12       Impact factor: 3.441

View more
  7 in total

1.  Mouse models for the study of fungal pneumonia: a collection of detailed experimental protocols for the study of Coccidioides, Cryptococcus, Fusarium, Histoplasma and combined infection due to Aspergillus-Rhizopus.

Authors:  Maged Muhammed; Marta Feldmesser; Lisa F Shubitz; Michail S Lionakis; Anita Sil; Yan Wang; Justin Glavis-Bloom; Russell E Lewis; John N Galgiani; Arturo Casadevall; Dimitrios P Kontoyiannis; Eleftherios Mylonakis
Journal:  Virulence       Date:  2012-05-01       Impact factor: 5.882

2.  Enhancement of nitric oxide synthesis by macrophages represents an additional mechanism of action for amphotericin B.

Authors:  N Mozaffarian; J W Berman; A Casadevall
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

Review 3.  Key issues concerning fungistatic versus fungicidal drugs.

Authors:  J R Graybill; D S Burgess; T C Hardin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-01       Impact factor: 3.267

4.  Effect of amphotericin B on capsule and cell size in Cryptococcus neoformans during murine infection.

Authors:  Oscar Zaragoza; Coralia Mihu; Arturo Casadevall; Joshua D Nosanchuk
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

5.  KY-62, a polyene analog of amphotericin B, for treatment of murine candidiasis.

Authors:  J R Graybill; L K Najvar; A Fothergill; T Hardin; M Rinaldi; C Lambros; S L Regen
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

6.  In vivo depletion of murine CD8 positive T cells impairs survival during infection with a highly virulent strain of Cryptococcus neoformans.

Authors:  C H Mody; G H Chen; C Jackson; J L Curtis; G B Toews
Journal:  Mycopathologia       Date:  1994-01       Impact factor: 2.574

7.  Comparative activities of Bay n7133, ICI 153,066, and ketoconazole in murine cryptococcosis.

Authors:  J R Graybill; S R Kaster; D J Drutz
Journal:  Antimicrob Agents Chemother       Date:  1983-12       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.